Mallinckrodt PLC (NYSE: MNK) has recently received a number of price target changes and ratings updates:

  • 9/6/2017 – Mallinckrodt PLC was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $40.00 price target on the stock, down previously from $65.00.
  • 9/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock.
  • 9/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $85.00 price target on the stock.
  • 9/6/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at UBS AG. They now have a $70.00 price target on the stock.
  • 9/5/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $52.00 price target on the stock.
  • 9/1/2017 – Mallinckrodt PLC was downgraded by analysts at ValuEngine from a “buy” rating to a “hold” rating.
  • 8/25/2017 – Mallinckrodt PLC was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 8/25/2017 – Mallinckrodt PLC had its price target lowered by analysts at Jefferies Group LLC from $70.00 to $60.00. They now have a “buy” rating on the stock.
  • 8/18/2017 – Mallinckrodt PLC was downgraded by analysts at BidaskClub from a “sell” rating to a “strong sell” rating.
  • 8/9/2017 – Mallinckrodt PLC was given a new $70.00 price target on by analysts at UBS AG. They now have a “buy” rating on the stock.
  • 8/9/2017 – Mallinckrodt PLC was given a new $56.00 price target on by analysts at Deutsche Bank AG. They now have a “buy” rating on the stock.
  • 8/9/2017 – Mallinckrodt PLC had its price target lowered by analysts at Raymond James Financial, Inc. from $65.00 to $58.00. They now have an “outperform” rating on the stock.
  • 8/9/2017 – Mallinckrodt PLC had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $65.00 price target on the stock, down previously from $69.00.
  • 8/9/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Mizuho. They now have a $70.00 price target on the stock, down previously from $73.00.
  • 8/8/2017 – Mallinckrodt PLC was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating.
  • 8/8/2017 – Mallinckrodt PLC was given a new $70.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 8/8/2017 – Mallinckrodt PLC was given a new $87.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 8/7/2017 – Mallinckrodt PLC was given a new $85.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.
  • 8/3/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at Jefferies Group LLC. They now have a $70.00 price target on the stock.
  • 7/28/2017 – Mallinckrodt PLC was given a new $70.00 price target on by analysts at Oppenheimer Holdings, Inc.. They now have a “buy” rating on the stock.
  • 7/28/2017 – Mallinckrodt PLC had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $69.00 price target on the stock.
  • 7/27/2017 – Mallinckrodt PLC was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mallinckrodt is currently focused on reshaping its product portfolio through strategic acquisitions and non-core asset divestitures. The company sold its Nuclear Imaging business due to lingering challenging conditions for quite some time. The company also sold its Intrathecal Therapy business to focus on its key areas. Acthar sales continue to be strong on the back of increased formulary positions and access for appropriate patients in both the commercial and public environments. The company is working on expanding Acthar's label further. The generic segment continues to face weakness as various product categories are witnessing stiff competition, which is hurting both their volumes and prices. Weakness in shares persist as shares have underperformed the Medical-Generic Drugs industry so far in 2017.”
  • 7/17/2017 – Mallinckrodt PLC was given a new $87.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 7/16/2017 – Mallinckrodt PLC was given a new $85.00 price target on by analysts at Piper Jaffray Companies. They now have a “buy” rating on the stock.

Mallinckrodt PLC (NYSE:MNK) opened at 35.33 on Monday. The stock’s market cap is $3.43 billion. Mallinckrodt PLC has a 1-year low of $34.51 and a 1-year high of $77.25. The firm has a 50-day moving average price of $39.95 and a 200 day moving average price of $43.93.

Mallinckrodt PLC (NYSE:MNK) last posted its quarterly earnings results on Tuesday, August 8th. The company reported $1.85 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.73 by $0.12. Mallinckrodt PLC had a return on equity of 15.28% and a net margin of 12.64%. The company had revenue of $824.50 million for the quarter, compared to analyst estimates of $829.56 million. During the same quarter last year, the company earned $2.03 EPS. Mallinckrodt PLC’s revenue for the quarter was down 4.9% compared to the same quarter last year. On average, equities research analysts anticipate that Mallinckrodt PLC will post $7.44 EPS for the current fiscal year.

In other news, insider Meredith B. Fischer purchased 1,280 shares of the company’s stock in a transaction that occurred on Wednesday, August 30th. The shares were purchased at an average price of $39.63 per share, for a total transaction of $50,726.40. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Corporate insiders own 0.53% of the company’s stock.

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs.

Receive News & Stock Ratings for Mallinckrodt PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mallinckrodt PLC and related stocks with our FREE daily email newsletter.